Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Hosted on MSN2d
Eli Lilly to Acquire Scorpion Therapeutics' Breast Cancer Candidate For up to $2.5 BillionEli Lilly (LLY) agreed to acquire an experimental treatment for breast cancer and other advanced solid tumors from Scorpion Therapeutics for up to $2.5 billion. The purchase price includes an upfront ...
Eli Lilly plans to acquire Scorpion's PI3Kα program for $2.5 billion, reinvesting Mounjaro and Zepbound profits to expand its precision medicines pipeline.
Scorpion Therapeutics Inc. is selling its lead drug in testing for breast cancer and other advanced solid tumors, to Eli ...
Bad news for Eli Lilly (NYSE: LLY) stock dragged down shares of rival companies in the market for GLP-1 diet drugs on Tuesday. Lilly updated investors on its expected revenue for 2024 this morning, ...
Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha ...
Boltwood Capital Management lessened its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 2.0% during the fourth quarter, according to its most recent 13F filing with the SEC.
Eli Lilly, the world’s largest drugmaker by ... including venture capital firms Lightspeed Venture Partners, Fidelity Management and Wellington Management, according to data provider PitchBook ...
Indianapolis: Eli Lilly and Company and Scorpion Therapeutics, Inc., a private biotechnology company developing small ...
The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Ka inhibitor currently in a Phase 1/2 clinical trialSTX-478 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback